Join Relmada Therapeutics for a virtual key opinion leader (KOL) event featuring Boris Chertin, MD (Department of Urology, Shaare Zedek Medical Center) and Yair Lotan, MD (UT Southwestern Medical Center), who will join company management to discuss topline efficacy and safety data from the Phase 2 study evaluating NDV-01 for the treatment of HG-NMIBC. The data will be presented at the American Urological Association meeting (AUA), being held April 26-29, 2025 in Las Vegas, Nevada.

NDV-01 is a novel, investigational, sustained-release gemcitabine/docetaxel formulation, designed as a ready-for-use intravesical therapy for the treatment of NMIBC (U.S. prevalence of ~600,000 patients, with ~62,000 newly diagnosed patients annually).

A live question and answer session will follow the formal presentation.